研究人員正在檢測特殊的血液樣本，以鑒別與追蹤蛋白質(zhì)生物學(xué)標(biāo)志物在血液中早期鑒別乳腺癌。

該研究是Power3醫(yī)療產(chǎn)品公司與Mercy婦女中心合作研究協(xié)議的一部分。這兩個機構(gòu)已經(jīng)從接受核磁共振乳房檢查的婦女中采集血液樣本。現(xiàn)在該數(shù)據(jù)庫收集了美國最大的與MRI檢測結(jié)果相關(guān)的血液樣本庫。測試的樣本越多，研究小組獲得的女性乳腺癌特異性的生物學(xué)特異性蛋白的精確性也越高。

Power3醫(yī)療公司首席安全官Ira. Goldknopf博士說：“我對我們利用血液來檢測與這種危害巨大的疾病相聯(lián)系的關(guān)鍵性蛋白質(zhì)的初步研究結(jié)果感到十分鼓舞。我們依然確信：在乳腺癌早期階段檢測的關(guān)鍵存在于某種蛋白質(zhì)的改變之中。”

。醫(yī)療公司正致力于探索蛋白質(zhì)痕跡、信號途徑以及疾病機制，以尋找合適技術(shù)檢測患者。這些發(fā)現(xiàn)正在被用于開發(fā)篩查與診斷技術(shù)，用于疾病的早期診斷與治療。

Protein Biomarkers for Breast Cancer
 
Researchers are testing special blood samples to identify and track protein biomarkers for the early indication of breast cancer in blood serum.

The research is part of a research agreement between Power3 Medical Products, Inc. (The Woodlands, TX, USA) and Mercy Women’s Center (Oklahoma City, OK, USA). The two groups have been collecting blood samples from women undergoing magnetic resonance imaging (MRI) of the breast. The database now accounts for the largest collection of samples tied to MRI results in the United States. The more samples tested, the more accurate the team can become in identifying specific protein biomarkers unique to women with breast cancer.

“I am encouraged by our initial discoveries utilizing blood serum to detect critical proteins associated with this devastating disease,” noted Dr. Ira Goldknopf, CSO of Power3 Medical. “We continue to believe that the key to detection of breast cancer at its earliest stages lies in the changes of one’s proteins.”

Power3 Medical is engaged in the discovery of protein footprints, pathways, and mechanisms of disease that its proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease.